Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer [Yahoo! Finance]
Cullinan Therapeutics, Inc. (CGEM)
NASDAQ:AMEX Investor Relations:
investorshub.advfn.com/consolidated-gems-inc-cgem-26232
Company Research
Source: Yahoo! Finance
and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024. "We are thrilled to welcome Jeff to the Obsidian leadership team as the company's Chief Financial Officer," said Madan Jagasia, M.D., Chief Executive Officer of Obsidian. "Jeff brings a breadth of strategic, operational, and financial experience in the life sciences industry, including building and growing private and public biotechnology companies. His expertise will be crucial as the company moves into its next stage of growth and continues advancing the clinical development of Obsidian's lead engineered tumor-infiltrating lymphocyte (TIL) cell therapy, OBX-115." "I am honored to join Obsidian at this pivotal time in the company's evolution," said Mr. Trigilio. "Obsidian has built a strong financial foundation with the support of top-tier life sciences investors and mutual funds. I am excited to join a leadership team with outstanding scientific and clinical
Show less
Read more
Impact Snapshot
Event Time:
CGEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEM alerts
High impacting Cullinan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGEM
News
- Cullinan Oncology, Inc. (NASDAQ: CGEM) had its price target lowered by analysts at HC Wainwright from $29.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Cullinan Oncology, Inc. (NASDAQ: CGEM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $36.00 price target on the stock.MarketBeat
- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsGlobeNewswire
- Cullinan Oncology, Inc. (NASDAQ: CGEM) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerGlobeNewswire
CGEM
Earnings
- 5/15/24 - Beat
CGEM
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 3
- 5/16/24 - Form S-3
- CGEM's page on the SEC website